Published in Crit Care on December 22, 2009
Hypometabolism and hypothermia in the rat model of endotoxic shock: independence of circulatory hypoxia. J Physiol (2014) 0.95
Hydroxyeyhyl starch: Controversies revisited. J Anaesthesiol Clin Pharmacol (2014) 0.80
Fluid-induced coagulopathy: does the type of fluid make a difference? Crit Care (2010) 0.77
Effect of synthetic colloid administration on coagulation in healthy dogs and dogs with systemic inflammation. J Vet Intern Med (2015) 0.77
Effects of colloid pre-loading on thromboelastography during elective intracranial tumor surgery in pediatric patients: hydroxyethyl starch 130/0.4 versus 5% human albumin. BMC Anesthesiol (2017) 0.75
Effect of intraoperative HES 6% 130/0.4 on the need for blood transfusion after major oncologic surgery: a propensity-matched analysis. Clinics (Sao Paulo) (2013) 0.75
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet (2001) 4.17
Hydroxyethyl starches: different products--different effects. Anesthesiology (2009) 3.23
Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg (2009) 2.72
Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev (2007) 2.45
Platelets: signaling cells in the immune continuum. Trends Immunol (2004) 2.18
Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev (2006) 2.08
An international view of hydroxyethyl starches. Intensive Care Med (1999) 1.88
Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology (2005) 1.88
Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth (2004) 1.62
Retracted A new plasma-adapted hydroxyethylstarch preparation: in vitro coagulation studies using thrombelastography and whole blood aggregometry. Anesth Analg (2007) 1.56
Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis (2005) 1.54
Mechanisms of the anti-inflammatory effects of hydroxyethyl starch demonstrated in a flow-based model of neutrophil recruitment by endothelial cells. Crit Care Med (2008) 1.44
Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost (2009) 1.36
New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol (2005) 1.35
Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost (2009) 1.26
Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med (2001) 1.26
Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci (2001) 1.21
The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg (2001) 1.17
The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg (2002) 1.12
In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg (2000) 1.06
Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg (2009) 1.01
HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth (2007) 1.01
Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg (1998) 1.00
A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion (2002) 0.98
Initial administration of hydroxyethyl starch vs lactated Ringer after liver trauma in the pig. Br J Anaesth (2008) 0.93
The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg (2008) 0.92
Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta Anaesthesiol Scand (2005) 0.92
The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost (1993) 0.92
Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets (2000) 0.90
Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med (2001) 0.89
Binding of hydroxyethyl starch molecules to the platelet surface. Anesth Analg (2003) 0.86
Hydroxyethyl starch 130/0.4 prevents the early pulmonary inflammatory response and oxidative stress after hemorrhagic shock and resuscitation in rats. Int Immunopharmacol (2009) 0.85
Retracted Balanced hydroxyethylstarch preparations: are they all the same? In-vitro thrombelastometry and whole blood aggregometry. Eur J Anaesthesiol (2009) 0.84
The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des (2004) 0.84
Retracted The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro. Vox Sang (2007) 0.83
[Monitoring of Perioperative Dilutional Coagulopathy Using the ROTEM Analyzer: Basic Principles and Clinical Examples]. Anasthesiol Intensivmed Notfallmed Schmerzther (2004) 0.83
Hydroxyethyl starch interferes with human blood ex vivo coagulation, platelet function and sedimentation. Acta Anaesthesiol Taiwan (2009) 0.81
Hydroxyethyl starch exhibits antiinflammatory effects in the intestines of endotoxemic rats. Anesth Analg (2006) 0.81
Formation of platelet-leukocyte conjugates in whole blood. Platelets (1997) 0.76
Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant (2006) 0.76
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med (2013) 17.37
Hydrocortisone therapy for patients with septic shock. N Engl J Med (2008) 15.85
Sepsis in European intensive care units: results of the SOAP study. Crit Care Med (2006) 11.78
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
Anemia and blood transfusion in critically ill patients. JAMA (2002) 7.83
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med (2010) 6.69
Perioperative fluid therapy with tetrastarch and gelatin in cardiac surgery--a prospective sequential analysis*. Crit Care Med (2013) 5.88
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med (2010) 4.64
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
Prognostic value of extravascular lung water in critically ill patients. Chest (2002) 4.46
A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care (2008) 4.31
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med (2015) 3.55
The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med (2013) 3.43
Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med (2012) 3.39
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med (2009) 3.30
Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med (2004) 3.16
Current practice in nutritional support and its association with mortality in septic patients--results from a national, prospective, multicenter study. Crit Care Med (2008) 3.12
Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med (2007) 2.97
Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med (2004) 2.95
Biomarkers of sepsis. Crit Care Med (2009) 2.88
Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med (2005) 2.73
A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med (2009) 2.60
Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med (2006) 2.47
Seeking worldwide professional consensus on the principles of end-of-life care for the critically ill. The Consensus for Worldwide End-of-Life Practice for Patients in Intensive Care Units (WELPICUS) study. Am J Respir Crit Care Med (2014) 2.46
Practice and perception--a nationwide survey of therapy habits in sepsis. Crit Care Med (2008) 2.43
High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med (2003) 2.43
Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med (2011) 2.30
Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med (2008) 2.27
Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant (2007) 2.25
The efficacy and safety of colloid resuscitation in the critically ill. Anesth Analg (2010) 2.23
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12
Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis. J Crit Care (2012) 2.11
Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med (2010) 2.08
Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med (2003) 2.01
New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev (2012) 2.01
An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence In Acutely Ill Patients (SOAP) study. Intensive Care Med (2006) 2.00
A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg (2011) 2.00
Fluid replacement with hydroxyethyl starch in critical care--a reassessment. Dtsch Arztebl Int (2013) 1.87
Fluctuations in serum sodium level are associated with an increased risk of death in surgical ICU patients. Crit Care Med (2013) 1.85
Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock (2009) 1.82
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med (2004) 1.80
The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care (2011) 1.77
Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care (2008) 1.76
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med (2008) 1.73
Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med (2012) 1.71
The heme oxygenase-carbon monoxide system: regulation and role in stress response and organ failure. Intensive Care Med (2008) 1.68
Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review. Intensive Care Med (2011) 1.66
Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int (2016) 1.65
The importance of religious affiliation and culture on end-of-life decisions in European intensive care units. Intensive Care Med (2007) 1.52
Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med (2005) 1.50
ADAMTS13--marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. Nephrol Dial Transplant (2010) 1.44
Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury. J Crit Care (2008) 1.43
The world's major religions' points of view on end-of-life decisions in the intensive care unit. Intensive Care Med (2007) 1.43
Venous oximetry. Curr Opin Crit Care (2006) 1.41
Stop sepsis-save lives: A call to join the global coalition for the World Sepsis Day. J Crit Care (2012) 1.38
Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock (2002) 1.35
Hepatic excretory function in sepsis: implications from biophotonic analysis of transcellular xenobiotic transport in a rodent model. Crit Care (2013) 1.29
Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest (2002) 1.28
Communication of end-of-life decisions in European intensive care units. Intensive Care Med (2005) 1.28
The obesity paradox in surgical intensive care unit patients. Intensive Care Med (2011) 1.27
Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med (2012) 1.27
Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets (2009) 1.26
Adjuvant selenium supplementation in the form of sodium selenite in postoperative critically ill patients with severe sepsis. Crit Care (2014) 1.26
Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. Crit Care (2005) 1.24
Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care (2006) 1.23
Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care (2009) 1.23
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care (2009) 1.22
Readmission to a surgical intensive care unit: incidence, outcome and risk factors. Crit Care (2008) 1.20
Characteristics of clinical sepsis reflected in a reliable and reproducible rodent sepsis model. J Surg Res (2011) 1.17
Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J (2005) 1.15
Attenuated inflammatory response in aged mice brains following stroke. PLoS One (2011) 1.14
Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study. PLoS One (2012) 1.12
Expression profiling: toward an application in sepsis diagnostics. Shock (2004) 1.11
Low and "supranormal" central venous oxygen saturation and markers of tissue hypoxia in cardiac surgery patients: a prospective observational study. Intensive Care Med (2010) 1.10
Epidemiology of and factors associated with end-of-life decisions in a surgical intensive care unit. Crit Care Med (2010) 1.10
Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care (2011) 1.09
Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry. Crit Care (2010) 1.09
The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis (2008) 1.09
Safety of modern starches used during surgery: misleading conclusions. Anesth Analg (2013) 1.08
Criticizing reporting standards fails to improve quality in animal research. Crit Care (2014) 1.07